Selected research
Industry Research
Rare Disease Therapeutic Industry Research Report 2026
Market perspective
The global Rare Disease Therapeutic market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Rare Disease Therapeutic market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Rare Disease Therapeutic market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Rare Disease Therapeutic market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Rare Disease Therapeutic include Bristol-Myers Squibb, Bayer, AstraZeneca, Pfizer, Novo Nordisk A/S, Sanofi SA, AbbVie, F Hoffmann-La Roche and Amgen, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Rare Disease Therapeutic market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Rare Disease Therapeutic.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Rare Disease Therapeutic Market by Company
Bristol-Myers Squibb
Bayer
AstraZeneca
Pfizer
Novo Nordisk A/S
Sanofi SA
AbbVie
F Hoffmann-La Roche
Amgen
Eisai
Novartis AG
Rare Disease Therapeutic Segment by Type
Biologics
Biosimilar
Small Molecules
Rare Disease Therapeutic Segment by Application
Hematologic Disease
Cancer
Infectious Disease
Cardiovascular Disease
Metabolic Disease
Endocrine Disease
Musculoskeletal Disease
Others
Rare Disease Therapeutic Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Rare Disease Therapeutic market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Rare Disease Therapeutic and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Rare Disease Therapeutic.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Rare Disease Therapeutic companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Biologics
- Biosimilar
- Small Molecules
Applications
- Hematologic Disease
- Cancer
- Infectious Disease
- Cardiovascular Disease
- Metabolic Disease
- Endocrine Disease
- Musculoskeletal Disease
- Others
Companies covered
- Bristol-Myers Squibb
- Bayer
- AstraZeneca
- Pfizer
- Novo Nordisk A/S
- Sanofi SA
- AbbVie
- F Hoffmann-La Roche
- Amgen
- Eisai
- Novartis AG
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Rare Disease Therapeutic by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Biologics
- 2.2.3 Biosimilar
- 2.2.4 Small Molecules
- 2.3 Rare Disease Therapeutic by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Hematologic Disease
- 2.3.3 Cancer
- 2.3.4 Infectious Disease
- 2.3.5 Cardiovascular Disease
- 2.3.6 Metabolic Disease
- 2.3.7 Endocrine Disease
- 2.3.8 Musculoskeletal Disease
- 2.3.9 Others
- 2.4 Assumptions and Limitations
3 Rare Disease Therapeutic Breakdown Data by Type
- 3.1 Global Rare Disease Therapeutic Historic Market Size by Type (2021-2026)
- 3.2 Global Rare Disease Therapeutic Forecasted Market Size by Type (2027-2032)
4 Rare Disease Therapeutic Breakdown Data by Application
- 4.1 Global Rare Disease Therapeutic Historic Market Size by Application (2021-2026)
- 4.2 Global Rare Disease Therapeutic Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Rare Disease Therapeutic Market Perspective (2021-2032)
- 5.2 Global Rare Disease Therapeutic Growth Trends by Region
- 5.2.1 Global Rare Disease Therapeutic Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Rare Disease Therapeutic Historic Market Size by Region (2021-2026)
- 5.2.3 Rare Disease Therapeutic Forecasted Market Size by Region (2027-2032)
- 5.3 Rare Disease Therapeutic Market Dynamics
- 5.3.1 Rare Disease Therapeutic Industry Trends
- 5.3.2 Rare Disease Therapeutic Market Drivers
- 5.3.3 Rare Disease Therapeutic Market Challenges
- 5.3.4 Rare Disease Therapeutic Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Rare Disease Therapeutic Players by Revenue
- 6.1.1 Global Top Rare Disease Therapeutic Players by Revenue (2021-2026)
- 6.1.2 Global Rare Disease Therapeutic Revenue Market Share by Players (2021-2026)
- 6.2 Global Rare Disease Therapeutic Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Rare Disease Therapeutic Head Office and Area Served
- 6.4 Global Rare Disease Therapeutic Players, Product Type & Application
- 6.5 Global Rare Disease Therapeutic Manufacturers Established Date
- 6.6 Global Rare Disease Therapeutic Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Rare Disease Therapeutic Market Size (2021-2032)
- 7.2 North America Rare Disease Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Rare Disease Therapeutic Market Size by Country (2021-2026)
- 7.4 North America Rare Disease Therapeutic Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Rare Disease Therapeutic Market Size (2021-2032)
- 8.2 Europe Rare Disease Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Rare Disease Therapeutic Market Size by Country (2021-2026)
- 8.4 Europe Rare Disease Therapeutic Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Rare Disease Therapeutic Market Size (2021-2032)
- 9.2 Asia-Pacific Rare Disease Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Rare Disease Therapeutic Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Rare Disease Therapeutic Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Rare Disease Therapeutic Market Size (2021-2032)
- 10.2 South America Rare Disease Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Rare Disease Therapeutic Market Size by Country (2021-2026)
- 10.4 South America Rare Disease Therapeutic Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Rare Disease Therapeutic Market Size (2021-2032)
- 11.2 Middle East & Africa Rare Disease Therapeutic Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Rare Disease Therapeutic Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Rare Disease Therapeutic Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Bristol-Myers Squibb
- 12.1.1 Bristol-Myers Squibb Company Information
- 12.1.2 Bristol-Myers Squibb Business Overview
- 12.1.3 Bristol-Myers Squibb Revenue in Rare Disease Therapeutic Business (2021-2026)
- 12.1.4 Bristol-Myers Squibb Rare Disease Therapeutic Product Portfolio
- 12.1.5 Bristol-Myers Squibb Recent Developments
- 12.2 Bayer
- 12.2.1 Bayer Company Information
- 12.2.2 Bayer Business Overview
- 12.2.3 Bayer Revenue in Rare Disease Therapeutic Business (2021-2026)
- 12.2.4 Bayer Rare Disease Therapeutic Product Portfolio
- 12.2.5 Bayer Recent Developments
- 12.3 AstraZeneca
- 12.3.1 AstraZeneca Company Information
- 12.3.2 AstraZeneca Business Overview
- 12.3.3 AstraZeneca Revenue in Rare Disease Therapeutic Business (2021-2026)
- 12.3.4 AstraZeneca Rare Disease Therapeutic Product Portfolio
- 12.3.5 AstraZeneca Recent Developments
- 12.4 Pfizer
- 12.4.1 Pfizer Company Information
- 12.4.2 Pfizer Business Overview
- 12.4.3 Pfizer Revenue in Rare Disease Therapeutic Business (2021-2026)
- 12.4.4 Pfizer Rare Disease Therapeutic Product Portfolio
- 12.4.5 Pfizer Recent Developments
- 12.5 Novo Nordisk A/S
- 12.5.1 Novo Nordisk A/S Company Information
- 12.5.2 Novo Nordisk A/S Business Overview
- 12.5.3 Novo Nordisk A/S Revenue in Rare Disease Therapeutic Business (2021-2026)
- 12.5.4 Novo Nordisk A/S Rare Disease Therapeutic Product Portfolio
- 12.5.5 Novo Nordisk A/S Recent Developments
- 12.6 Sanofi SA
- 12.6.1 Sanofi SA Company Information
- 12.6.2 Sanofi SA Business Overview
- 12.6.3 Sanofi SA Revenue in Rare Disease Therapeutic Business (2021-2026)
- 12.6.4 Sanofi SA Rare Disease Therapeutic Product Portfolio
- 12.6.5 Sanofi SA Recent Developments
- 12.7 AbbVie
- 12.7.1 AbbVie Company Information
- 12.7.2 AbbVie Business Overview
- 12.7.3 AbbVie Revenue in Rare Disease Therapeutic Business (2021-2026)
- 12.7.4 AbbVie Rare Disease Therapeutic Product Portfolio
- 12.7.5 AbbVie Recent Developments
- 12.8 F Hoffmann-La Roche
- 12.8.1 F Hoffmann-La Roche Company Information
- 12.8.2 F Hoffmann-La Roche Business Overview
- 12.8.3 F Hoffmann-La Roche Revenue in Rare Disease Therapeutic Business (2021-2026)
- 12.8.4 F Hoffmann-La Roche Rare Disease Therapeutic Product Portfolio
- 12.8.5 F Hoffmann-La Roche Recent Developments
- 12.9 Amgen
- 12.9.1 Amgen Company Information
- 12.9.2 Amgen Business Overview
- 12.9.3 Amgen Revenue in Rare Disease Therapeutic Business (2021-2026)
- 12.9.4 Amgen Rare Disease Therapeutic Product Portfolio
- 12.9.5 Amgen Recent Developments
- 12.10 Eisai
- 12.10.1 Eisai Company Information
- 12.10.2 Eisai Business Overview
- 12.10.3 Eisai Revenue in Rare Disease Therapeutic Business (2021-2026)
- 12.10.4 Eisai Rare Disease Therapeutic Product Portfolio
- 12.10.5 Eisai Recent Developments
- 12.11 Novartis AG
- 12.11.1 Novartis AG Company Information
- 12.11.2 Novartis AG Business Overview
- 12.11.3 Novartis AG Revenue in Rare Disease Therapeutic Business (2021-2026)
- 12.11.4 Novartis AG Rare Disease Therapeutic Product Portfolio
- 12.11.5 Novartis AG Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst